As of Aug 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to ...

Financial Performance - Fourth quarter fiscal year 2024 revenues reached $59.9 billion, a 12% increase from the prior year[2] - Non-GAAP operating earnings for Q4 FY24 increased 14% to $605 million, while non-GAAP diluted EPS rose 29% to $1.84[5] - Fiscal year 2024 revenues totaled $226.8 billion, an 11% increase from fiscal year 2023, with non-GAAP operating earnings growing 16% to $2.4 billion[3] - Revenue for Q4 2024 was $59,867 million, a 12% increase from $53,421 million in Q4 2023[25] - Total revenue for the fiscal year 2024 was $210,019 million, representing an 11% growth compared to $188,814 million in 2023[33] - The Pharmaceutical and Specialty Solutions segment reported revenue of $55,608 million in Q4 2024, a 13% increase from $49,373 million in Q4 2023[33] - Total segment revenue for Fiscal Year 2024 reached $226,912 million, reflecting an 11% growth compared to the previous year[45] - Pharmaceutical and Specialty Solutions segment revenue was $210,019 million, with a growth rate of 11%[45] - GAAP revenue for fiscal year 2024 reached $7,414 million, representing an 8% increase compared to $6,874 million in fiscal year 2023[39] Earnings and Profitability - Cardinal Health's operating earnings for fiscal year 2024 were $1,243 million, a 65% increase from $752 million in fiscal year 2023[25] - Net earnings attributable to Cardinal Health, Inc. for Q4 2024 were $235 million, compared to a net loss of $56 million in Q4 2023[25] - Basic earnings per share for Q4 2024 was $0.96, a significant improvement from a loss of $0.22 per share in Q4 2023[25] - The company reported a net income of $1,201 million for fiscal year 2024, with a diluted EPS of $3.45, compared to a net income of $663 million and diluted EPS of $1.26 in fiscal year 2023[39] - Non-GAAP operating earnings for fiscal year 2024 were $2,414 million, a 16% growth from $2,076 million in fiscal year 2023[39] - Non-GAAP diluted EPS for Q4 2024 was $1.84, a 29% increase from $1.43 in Q4 2023[36] - Total segment profit for Fiscal Year 2024 was $2,530 million, representing a 19% increase year-over-year[45] Cash Flow and Assets - Cash flows from operating activities for Q4 2024 were $2,082 million, up from $871 million in Q4 2023[31] - The net cash provided by operating activities for fiscal year 2024 was $3,762 million, up from $2,844 million in fiscal year 2023[42] - Non-GAAP adjusted free cash flow for fiscal year 2024 was $3,942 million, compared to $2,853 million in fiscal year 2023, indicating a significant increase[42] - Cardinal Health's cash and equivalents increased to $5,133 million as of June 30, 2024, compared to $4,076 million as of June 30, 2023[29] - Total assets increased to $45,121 million as of June 30, 2024, compared to $43,349 million as of June 30, 2023[29] Segment Performance - The Pharmaceutical and Specialty Solutions segment reported Q4 FY24 revenue of $55.6 billion, a 13% increase year-over-year[7] - Segment profit for Global Medical Products and Distribution increased to $47 million in Q4 2024, compared to $7 million in Q4 2023, indicating a notable improvement[33] - Global Medical Products and Distribution segment profit improved significantly to $47 million in Q4 FY24, driven by net inflationary impacts mitigation[10] - The Other segment's revenue increased 15% to $1.2 billion in Q4 FY24, supported by growth across multiple operating segments[11] - Global Medical Products and Distribution segment revenue decreased slightly to $12,381 million, with a growth rate of 1%[45] Guidance and Future Outlook - The company raised its fiscal year 2025 non-GAAP EPS guidance to $7.55 to $7.70, up from at least $7.50 previously communicated[5] - Cardinal Health aims for approximately $300 million in segment profit from the GMPD Improvement Plan by fiscal year 2026[15] - The company anticipates ongoing inflationary pressures and competitive challenges impacting future performance[23] - The company plans to continue its market expansion and product development strategies in the upcoming fiscal year[39] - Cardinal Health is focusing on restructuring efforts, with $175 million allocated for employee severance and restructuring costs in fiscal year 2024[39] Impairments and Adjustments - The company recorded pre-tax goodwill impairment charges of $675 million related to the GMPD segment in fiscal year 2024[26] - Cardinal Health recorded cumulative pre-tax goodwill impairment charges of $675 million during fiscal 2024, impacting overall financial performance[36] - The company incurred $634 million in impairments and gains/losses on disposal of assets for fiscal year 2024[39] - The company incurred $90 million in pre-tax goodwill impairment charges related to GMPD in Q3 2024[52] Non-GAAP Measures - Non-GAAP operating earnings exclude various charges and costs, providing a clearer view of operational performance[70] - Non-GAAP net earnings attributable to Cardinal Health, Inc. adjust for specific items, reflecting the company's true profitability[72] - Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. is calculated based on adjusted net earnings divided by diluted weighted-average shares outstanding[74] - Non-GAAP adjusted free cash flow measures cash generated from operations after capital expenditures, excluding certain litigation-related payments[75] - Non-GAAP effective tax rate is adjusted for specific charges, providing insight into the company's tax efficiency[73] - The focus on non-GAAP measures indicates a strategy to present a more favorable view of financial health to investors[72] - The exclusion of litigation recoveries and charges in cash flow calculations emphasizes the company's commitment to transparency in financial reporting[75]

Cardinal Health, Inc. CAH is set to release earnings results for its fourth quarter, before the opening bell on Aug. 14, 2024.Analysts expect the Dublin, Ohio-based company to report quarterly earnings at $1.73 per share, up from $1.55 per share in the year-ago period. Cardinal Health is expected to report quarterly revenue of $58.64 billion for the quarter, compared to $53.45 billion a year earlier, according to data from Benzinga Pro.On May 7, Cardinal Health approved an increase to its quarterly dividend ...

Core Viewpoint - Cardinal Health, Inc. is set to report its fourth-quarter fiscal 2024 results on August 14, with expectations of earnings and revenue growth compared to the previous year [1][2]. Group 1: Earnings and Revenue Estimates - The consensus estimate for earnings in the fiscal fourth quarter is $1.72 per share, reflecting a 10.9% increase from the prior year's quarter [2]. - Revenue expectations are pegged at $58.72 billion, indicating a year-over-year growth of 9.9% [2]. Group 2: Segment Performance - Cardinal Health has restructured its reporting into new operating segments, including Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution, and others [3]. - The Pharmaceutical segment reported revenues of approximately $50.7 billion in the third quarter of fiscal 2024, marking a 9% year-over-year increase, driven by branded pharmaceutical sales growth [3][4]. - The Medical segment's revenues grew by 4% year over year, supported by growth in at-Home Solutions and GMPD, with a profit of $20 million in the last reported quarter [4]. Group 3: Strategic Developments - In March 2024, Cardinal Health completed the acquisition of Specialty Networks, which is expected to enhance its offerings in urology, GI, and rheumatology, with plans for further investment in fiscal 2025 [5]. - The company is constructing a new distribution center in South Carolina, which is anticipated to improve supply chain efficiency and revenue generation [6]. Group 4: Earnings Prediction Model - The current Zacks model indicates that Cardinal Health does not conclusively predict an earnings beat for this reporting cycle, with an Earnings ESP of -0.17% and a Zacks Rank of 3 [7][8].

Analysts on Wall Street project that Cardinal Health (CAH) will announce quarterly earnings of $1.72 per share in its forthcoming report, representing an increase of 11% year over year. Revenues are projected to reach $58.72 billion, increasing 9.9% from the same quarter last year.Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forec ...

The market expects Cardinal Health (CAH) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be release ...

In the latest market close, Cardinal Health (CAH) reached $99.52, with a +1.18% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 1.04% for the day. Elsewhere, the Dow saw an upswing of 0.76%, while the tech-heavy Nasdaq appreciated by 1.03%.The prescription drug distributor's shares have seen an increase of 1.53% over the last month, surpassing the Medical sector's gain of 0.21% and the S&P 500's loss of 6.74%.The investment community will be closely monitori ...

DNY59 CAH stock: unfavorable PEG ratio I last covered Cardinal Health (NYSE:CAH) stock a bit more than 3 months ago. As you can see from the chart below, my last article, titled "Cardinal Health: Solid Business But Overvalued", was published on April 18, 2024, and argued for a HOLD thesis on the stock. The holding rating was mainly based on the following considerations: Cardinal Health is overvalued, with a dividend yield lower than its historical average and a high P/E ratio. Growth projections for the ...

The latest trading session saw Cardinal Health (CAH) ending at $100.83, denoting a +0.57% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 1.08% for the day. Meanwhile, the Dow gained 0.75%, and the Nasdaq, a tech-heavy index, added 2.64%. Coming into today, shares of the prescription drug distributor had gained 3.85% in the past month. In that same time, the Medical sector gained 0.71%, while the S&P 500 lost 0.44%. Market participants will be closely fo ...

Cardinal Health (CAH) closed the latest trading day at $96.71, indicating a +0.91% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 2.32%. Elsewhere, the Dow saw a downswing of 1.25%, while the tech-heavy Nasdaq depreciated by 3.64%.The prescription drug distributor's shares have seen a decrease of 7.07% over the last month, not keeping up with the Medical sector's gain of 0.32% and the S&P 500's gain of 1.79%.Analysts and investors alike will be k ...